IM Cannabis Competitors

RIV Capital (TSE:RIV) and IM Cannabis (CNSX:IMCC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Earnings & Valuation

This table compares RIV Capital and IM Cannabis' top-line revenue, earnings per share and valuation.

IM Cannabis has lower revenue, but higher earnings than RIV Capital.

Analyst Recommendations

This is a summary of current ratings and target prices for RIV Capital and IM Cannabis, as reported by MarketBeat.

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 65.29%.

Profitability

This table compares RIV Capital and IM Cannabis' net margins, return on equity and return on assets.

Summary

RIV Capital beats IM Cannabis on 1 of the 1 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares IM Cannabis and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share (EPS) and valuation.

IM Cannabis has higher earnings, but lower revenue than Willow Biosciences Inc. (WLLW.TO).

Analyst Ratings

This is a summary of current ratings for IM Cannabis and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.com.

Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, indicating a potential upside of 58.45%.

Profitability

This table compares IM Cannabis and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Summary

Willow Biosciences Inc. (WLLW.TO) beats IM Cannabis on 1 of the 1 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and MediPharm Labs (TSE:LABS) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and MediPharm Labs' revenue, earnings per share and valuation.

IM Cannabis has higher earnings, but lower revenue than MediPharm Labs.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and MediPharm Labs, as provided by MarketBeat.

MediPharm Labs has a consensus price target of C$1.53, indicating a potential upside of 194.23%.

Profitability

This table compares IM Cannabis and MediPharm Labs' net margins, return on equity and return on assets.

Summary

MediPharm Labs beats IM Cannabis on 2 of the 2 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Khiron Life Sciences (CVE:KHRN) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and Khiron Life Sciences' revenue, earnings per share and valuation.

IM Cannabis has higher earnings, but lower revenue than Khiron Life Sciences.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and Khiron Life Sciences, as provided by MarketBeat.

Khiron Life Sciences has a consensus price target of C$1.20, indicating a potential upside of 110.53%.

Profitability

This table compares IM Cannabis and Khiron Life Sciences' net margins, return on equity and return on assets.

Summary

Khiron Life Sciences beats IM Cannabis on 1 of the 1 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Delta 9 Cannabis (TSE:DN) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and Delta 9 Cannabis' revenue, earnings per share and valuation.

IM Cannabis has higher earnings, but lower revenue than Delta 9 Cannabis.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and Delta 9 Cannabis, as provided by MarketBeat.

Delta 9 Cannabis has a consensus price target of C$1.24, indicating a potential upside of 110.17%.

Profitability

This table compares IM Cannabis and Delta 9 Cannabis' net margins, return on equity and return on assets.

Summary

Delta 9 Cannabis beats IM Cannabis on 2 of the 2 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Meta Growth (CVE:META) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and Meta Growth's revenue, earnings per share and valuation.

IM Cannabis has higher earnings, but lower revenue than Meta Growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and Meta Growth, as provided by MarketBeat.

Profitability

This table compares IM Cannabis and Meta Growth's net margins, return on equity and return on assets.

Summary

Meta Growth beats IM Cannabis on 1 of the 1 factors compared between the two stocks.